Lipocine (LPCN) Cash from Operations (2011 - 2025)
Lipocine's (LPCN) quarterly Cash from Operations came in at 2985723.0 in Q3 2025, down 5.39% YoY from 3155972.02 in Q3 2024, and down 58.29% on a QoQ basis from 1886234.0 in Q2 2025.
Lipocine (LPCN) Cash from Operations (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Cash from Operations data on file, last reported at 2985723.0 in Q3 2025.
- Quarterly Cash from Operations fell 5.39% year-over-year to 2985723.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 5139287.0 (down 3.92% YoY) and the FY2024 annual result came in at 1221233.0, up 89.71% from the prior year.
- Cash from Operations eased to 2985723.0 in Q3 2025, from 1886234.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 8994540.0 in Q4 2021 to a low of 6980787.0 in Q3 2021.
- A 5-year average of 1910976.84 and a median of 2606032.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations soared 344.15% — and 2025, when it slumped 181.8%.
- Tracing LPCN's Cash from Operations over 5 years: stood at 8994540.0 in 2021, then slumped by 120.44% to 1838914.0 in 2022, then retreated by 9.97% to 2022305.0 in 2023, then soared by 184.16% to 1701927.0 in 2024, then plunged by 275.43% to 2985723.0 in 2025.
- The last three Cash from Operations figures came in at 2985723.0 (Q3 2025), 1886234.0 (Q2 2025), and 1969257.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.99 Mn |
| Sep 30, 2025 | -2.99 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.83 Mn |
| Jun 30, 2024 | -2.50 Mn |
| Jun 30, 2024 | -2.50 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Jun 30, 2023 | -3.31 Mn |
| Jun 30, 2023 | -3.31 Mn |